By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Adaptimmune Ltd. 

57c Milton Park

Abingdon  Oxfordshire  OX14 4RX  United Kingdom
Phone: +44-(0)-1235-438-642 Fax: +44-(0)-1235-438-607


Key Statistics

Ownership: Public

Web Site: Adaptimmune
Symbol: ADAP

Company News
Adaptimmune (ADAP) Reports Third Quarter 2016 Financial Results 11/10/2016 8:23:30 AM
Adaptimmune (ADAP) Announces Collaboration With Merck & Co. (MRK) MSD To Evaluate KEYTRUDA┬« (Pembrolizumab) In Combination With NY-ESO SPEAR T-Cell Therapy In Multiple Myeloma 10/28/2016 7:50:35 AM
Adaptimmune (ADAP) Announces Initiation Of Triple Tumor Study To Evaluate Its SPEAR T-Cell Therapy Targeting MAGE-A10 10/18/2016 7:58:10 AM
After Setback, Adaptimmune (ADAP) Revamps T Cell Study 10/14/2016 6:48:02 AM
Adaptimmune (ADAP) Makes Move to Save Ovarian Cancer Study By Readjusting Its Trial Protocol 10/12/2016 8:15:30 AM
MD Anderson Cancer Center And Adaptimmune (ADAP) Form Strategic Alliance To Advance Development Of Immunotherapies Targeting Multiple Cancers 9/26/2016 7:32:26 AM
FDA Hits Adaptimmune (ADAP) with a Partial Hold on Pivotal Sarcoma Trial, Stock Tanks 8/4/2016 6:10:54 AM
Adaptimmune (ADAP) Receives Access To Priority Medicines (PRIME) Regulatory Support For Its SPEAR T-Cell Therapy Targeting NY-ESO For Treatment Of Soft Tissue Sarcoma 7/28/2016 10:15:53 AM
Adaptimmune (ADAP) Receives Orphan Drug Designation In The European Union For Its NY-ESO SPEAR T-Cell Therapy For Treatment Of Soft Tissue Sarcoma 7/26/2016 8:00:11 AM
Adaptimmune (ADAP) To Present At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/3/2016 8:20:18 AM